top of page
it's where dermatology lives


ARC-ZOR_NL_200409_OneBrand_MEDIA_Wban_EN_1260x126


ARC-ZOR_NL_200409_OneBrand_MEDIA_Wban_EN_1260x126
1/2


Key “lipid transporter” for skin barrier integrity identified
MFSD2A is required for the uptake of LPCs containing linoleic acid (LPC18:2) from the blood for normal development of the epidermis. The absence of MFSD2A leads to increased skin inflammation and thickening of the epidermis. Photo by: Bernice Wong Researchers at Duke-NUS Medical School in Singapore have pinpointed a lipid transporter that enables epidermal cells to import key fatty acids from the bloodstream, a mechanism they say is critical for preserving skin barrier integr
Allan Ryan
23 minutes ago2 min read


Topical LSD1 inhibitor shows promise for cSSC Tx
Squamous cell carcinoma in situ. Photo by Klaus D. Peter via Wikimedia Commons Findings from a preclinical study show a topical cream that blocks the immune-suppressing enzyme LSD1 suppressed tumour growth in two models of cutaneous squamous cell carcinoma (cSCC). The study, published in the Journal of Clinical Investigation , describes how the cream, developed by researchers at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, prevents LSD1
John Evans
3 days ago2 min read


VIDEO: Concomitant topical insulin and microneedling may increase effectiveness of treatment in acne patients
Adjunct topical insulin alongside microneedling decreases the rate of poor improvement scores in acne patients.
Jeremy Visser
5 days ago1 min read


Assessing topical estrogen for menopausal skin
Shoshana Marmon, MD, PhD Some improvements seen in skin thickness and collagen, but study designs varied Topical estrogen is emerging as a sought-after option for menopausal skin changes, but dermatologists caution that the evidence base remains limited and safety questions unresolved, according to a cover article in the Feb. 2026 issue of The Chronicle of Skin & Allergy . Patient interest in facial estrogen preparations has grown in parallel with menopause-focused marketing
Allan Ryan
Mar 162 min read


Dupilumab restores skin barrier in young children with AD
Child with Atopic Dermatitis Photo by Eisfelder via Wikimedia Commons A new study shows that treatment with dupilumab significantly restores skin barrier function and reduces inflammation in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Researchers found improvements not only in visible AD lesions but also in clinically unaffected skin, highlighting the systemic nature of the disease. The findings were published in Annals of Allergy, Asthma & Imm
John Evans
Mar 132 min read


VIDEO: Alopecia areata linked to higher risk of AD in patients
Patients with moderate to severe alopecia areata have a higher risk of developing AD.
Jeremy Visser
Mar 111 min read
Featured Posts


bottom of page
